Alamar Biosciences (NASDAQ:ALMR) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Alamar Biosciences (NASDAQ:ALMR) to a hold rating in a research report released on Wednesday,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Bank of America initiated coverage on shares of Alamar Biosciences in a research report on Tuesday. They set a “neutral” rating and a $27.00 price objective for the company. Wall Street Zen upgraded shares of Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. Stifel Nicolaus began coverage on shares of Alamar Biosciences in a research report on Tuesday. They set a “buy” rating and a $28.00 price objective for the company. TD Cowen began coverage on shares of Alamar Biosciences in a report on Tuesday. They issued a “buy” rating and a $30.00 target price for the company. Finally, Leerink Partners began coverage on shares of Alamar Biosciences in a report on Tuesday. They issued an “outperform” rating and a $35.00 target price for the company. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Alamar Biosciences Trading Down 2.2%

ALMR stock opened at $22.51 on Wednesday. Alamar Biosciences has a 52 week low of $21.50 and a 52 week high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last released its quarterly earnings data on Friday, May 8th. The company reported ($1.74) EPS for the quarter. The business had revenue of $26.04 million for the quarter.

Insider Activity

In other news, Director Nicholas Naclerio bought 235,294 shares of the stock in a transaction dated Monday, April 20th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the acquisition, the director owned 507,076 shares of the company’s stock, valued at $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the stock in a transaction dated Monday, April 20th. The stock was purchased at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the acquisition, the insider directly owned 507,076 shares in the company, valued at approximately $8,620,292. The trade was a 86.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.